{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:43:50Z","timestamp":1789908230989,"version":"4.0.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1038\/ajg.2012.464","type":"journal-article","created":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T08:58:06Z","timestamp":1363078686000},"page":"583-593","source":"Crossref","is-referenced-by-count":93,"title":["Anti-Tumor Necrosis Factor Therapy Is Associated With Infections after Abdominal Surgery in Crohn's Disease Patients"],"prefix":"10.14309","volume":"108","author":[{"given":"Ali","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond K","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H","family":"Flasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease.","volume":"347","author":"Podolsky","year":"2002","journal-title":"N Engl J Med"},{"key":"R2-20-20210210","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/138945010790309876","article-title":"Efficacy of anti-TNF in Crohns disease: how does it work?","volume":"11","author":"Chowers","year":"2010","journal-title":"Curr Drug Targets"},{"key":"R3-20-20210210","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor -producing cells in the intestinal mucosa of children with inflammatory bowel disease.","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"R4-20-20210210","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000320413","article-title":"State-of-the-art: immunosuppression and biologic therapy.","volume":"28","author":"Sandborn","year":"2010","journal-title":"Dig Dis"},{"key":"R5-20-20210210","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2009.02.001","article-title":"Biological therapies for inflammatory bowel diseases.","volume":"136","author":"Rutgeerts","year":"2009","journal-title":"Gastroenterology"},{"key":"R6-20-20210210","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases.","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"R7-20-20210210","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/ibd.21504","article-title":"Perioperative complications in inflammatory bowel disease.","volume":"17","author":"Beddy","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R8-20-20210210","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cgh.2007.02.016","article-title":"Serious adverse events with infliximab: analysis of spontaneously reported adverse events.","volume":"5","author":"Hansen","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-20-20210210","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1016\/S0016-5085(11)63209-5","article-title":"Safety of infliximab and other Crohns disease therapies: treat (TM) registry data with a mean of 5 years of follow-up.","volume":"140","author":"Lichtenstein","year":"2011","journal-title":"Gastroenterology"},{"key":"R12-20-20210210","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1463-1318.2010.02469.x","article-title":"Surgical resection in Crohns disease: is immunosuppressive medication associated with higher postoperative infection rates?","volume":"13","author":"Canedo","year":"2011","journal-title":"Colorectal Dis"},{"key":"R13-20-20210210","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohns disease treated perioperatively with infliximab or immunosuppressive therapy.","volume":"99","author":"Colombel","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R14-20-20210210","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00268-009-9957-x","article-title":"Effect of perioperative immunosuppressive medication on early outcome in Crohns disease patients.","volume":"33","author":"Indar","year":"2009","journal-title":"World J Surg"},{"key":"R15-20-20210210","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ibd.21860","article-title":"Infliximab does not affect postoperative complication rates in Crohns patients undergoing abdominal surgery.","volume":"18","author":"Kasparek","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R17-20-20210210","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2004.01904.x","article-title":"The risk of post-operative complications associated with infliximab therapy for Crohns disease: a controlled cohort study.","volume":"19","author":"Marchal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-20-20210210","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1007\/s11605-008-0646-0","article-title":"Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohns patients.","volume":"12","author":"Appau","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"R21-20-20210210","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/00054725-201112002-00046","article-title":"The effect of preoperative infliximab therapy in Crohns patients on post-operative complications: a meta-analysis.","volume":"17","author":"Rosenfeld","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R23-20-20210210","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R24-20-20210210","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2407-4-94","article-title":"An electronic application for rapidly calculating Charlson comorbidity score.","volume":"4","author":"Hall","year":"2004","journal-title":"BMC Cancer"},{"key":"R25-20-20210210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohns disease: TREAT registry.","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-20-20210210","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.14309\/00000434-201010001-01287","article-title":"Does immunosuppressive therapy increase operative morbidity in Patients with Crohns disease?","volume":"105","author":"Bafford","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R27-20-20210210","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00464-009-0759-x","article-title":"Laparoscopic surgery for inflammatory bowel disease: does weight matter?","volume":"24","author":"Canedo","year":"2010","journal-title":"Surg Endosc"},{"key":"R28-20-20210210","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00384-011-1236-2","article-title":"Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience.","volume":"26","author":"Rizzo","year":"2011","journal-title":"Int J Colorectal Dis"},{"key":"R30-20-20210210","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1007\/s10620-011-1785-9","article-title":"Postoperative infliximab is not associated with an increase in adverse events in Crohns disease.","volume":"56","author":"Regueiro","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R31-20-20210210","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00384-008-0534-9","article-title":"Intraabdominal septic complications following bowel resection for Crohns disease: detrimental influence on long-term outcome.","volume":"23","author":"Iesalnieks","year":"2008","journal-title":"Int J Colorectal Dis"},{"key":"R32-20-20210210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: an open randomised trial.","volume":"371","author":"DHaens","year":"2008","journal-title":"Lancet"},{"key":"R33-20-20210210","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-300934","article-title":"Early use of immunosuppressives or TNF antagonists for the treatment of Crohns disease: time for a change.","volume":"60","author":"Ordas","year":"2011","journal-title":"Gut"},{"key":"R34-20-20210210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohns disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R35-20-20210210","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0016-5085(11)60149-2","article-title":"The presence or concomitant inflammatory bowel disease is associated with an increased risk for post-operative complication of cholecystectomy.","volume":"140","author":"Choure","year":"2011","journal-title":"Gastroenterology"},{"key":"R36-20-20210210","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/j.1572-0241.2008.01942.x","article-title":"Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery.","volume":"103","author":"Subramanian","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R37-20-20210210","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0016-5085(11)60251-5","article-title":"Adalimumab levels detected in cord blood and infants exposed in utero.","volume":"140","author":"Mahadevan","year":"2011","journal-title":"Gastroenterology"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2012464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012464","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201304000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:45:46Z","timestamp":1786542346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201304000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2012.464","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717989777.793472898","asserted-by":"object"}]},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}